Sozi Pedro Tulante

340B Meets The FCA In The Ninth Circuit: What The Pharmaceutical Industry And Investors Need To Know OnPoint Thu Sep 03 2026 The Ninth Circuit's Adventist Decision Lets 340B Covered Entities Bring FCA Qui Tam Suits Over Drug Pricing, Raising New Risks For Manufacturers And Investors.

Federal Contractors Face Escalating Enforcement With New Executive Order Targeting Racial Discrimination As Employers Navigate Increasingly Complex DEI Landscape

EKRA Heats Up: What U.S. Laboratories And Investors Need To Know

Supreme Court Unanimously Rejects Heightened Pleading Requirements For "Majority Group" Discrimination Claims

The Formation Of The DOJ Civil Rights Fraud Initiative Gives Teeth To Trump Administration's Intent To Use The False Claims Act To Target "Illegal DEI"